Blogs
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
- No Questions Asked: FDA’s Psychedelics Public Hearing
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Approvals to Access: A Crude Schematic
- Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
Magazines
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
- No Questions Asked: FDA’s Psychedelics Public Hearing
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Approvals to Access: A Crude Schematic
- Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
Record Labels
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
- No Questions Asked: FDA’s Psychedelics Public Hearing
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Approvals to Access: A Crude Schematic
- Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
News stories about record stores
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
- No Questions Asked: FDA’s Psychedelics Public Hearing
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Approvals to Access: A Crude Schematic
- Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM